ClinicalTrials.Veeva

Menu

Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

C

Cellect Biotechnology

Status

Unknown

Conditions

Hodgkin Lymphoma, Adult
Acute Lymphoblastic Leukemia (ALL)
Non Hodgkin Lymphoma (NHL)
Acute Myelogenous Leukemia (AML)

Treatments

Other: non intervational

Study type

Observational

Funder types

Industry

Identifiers

NCT03260101
ApoGraft01 FU

Details and patient eligibility

About

This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.

Subjects who completed ApoGraft-01 study and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend in-clinic visits up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence), physical examination, safety laboratory and concomitant medication use.

Enrollment

12 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. Subjects who completed study ApoGraft-01 through 180 days (6 months) post-transplantation
  2. Ability to comply with the requirements of the study.
  3. Signed written informed consent

Trial design

12 participants in 1 patient group

one group, ApoGraft Follow up Study
Description:
Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
Treatment:
Other: non intervational

Trial contacts and locations

1

Loading...

Central trial contact

Shai Yarkoni, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems